Poster: CML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI)
Clinical Lymphoma Myeloma and Leukemia（2022）
摘要
The primary endpoint is rate of MMR at 12 months. Secondary endpoints include additional efficacy outcomes at 3, 6, 18, and 24 months and safety measures.
更多查看译文
关键词
CML,chronic myeloid leukemia,asciminib,2L,dose escalation,Trial-in-Progress
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要